Effect of DCLK1 knockout on migration and invasion of esophageal squamous carcinoma cells

doi:10.3969/j.issn.1006-7795.2019.03.017

Abstract

Abstract: Objective To investigate the effect of doublecortin-like kinase 1 (DCLK1) knockout on the migration and invasion of esophageal squamous carcinoma (ESCC) cells and its potential mechanism. Methods CRISPR/Cas9 genome-editing technique was used to knock out DCLK1 gene in ESCC cells (Kyse450, Kyse70). Wound healing assays and Transwell assays were performed to assess the effects of DCLK1 knockout on migration and invasion of ESCC cells. Western blotting was used to detect the expression of epithelial-mesenchymal transition (EMT) related transcription factors in DCLK1 knockout cell lines. The correlation between DCLK1 expression and epithelial-mesenchymal transition (EMT) associated transcription factors were analyzed among 95 ESCC patients from The Cancer Genome Atla (TCGA) database.Results CRISPR/Cas9 technology efficiently disrupted the DCLK1 gene and abrogated its expression in ESCC cell lines. DCLK1 deficiency significantly inhibited ESCC cells migration and invasion (P<0.05), and up-regulated the expression of the epithelial marker E-cadherin, but decreased the levels of mesenchymal markers, such as Vimentin, ZEB1, Slug and Snail in ESCC cell lines (P<0.05). In addition, TCGA database analysis showed that DCLK1 is associated with EMT associated transcription factors in patients with ESCC. Conclusion DCLK1 knockout can affect the migration and invasion of ESCC cells by inhibiting EMT process.

Key words: doublecortin-like kinase 1(DCLK1), esophageal squamous cell carcinoma, epithelial-mesenchymal transition, migration, invasion

CLC Number:

R735.1

Fan Xiaona, Yao Jiannan, Ge Yang, An Guangyu, Li Ying. Effect of DCLK1 knockout on migration and invasion of esophageal squamous carcinoma cells[J]. Journal of Capital Medical University, 2019, 40(3): 417-423.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2019.03.017

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2019/V40/I3/417

References

[1] Siegel R L, Miller K D and Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018,68(1):7-30.
[2] Arnold M, Soerjomataram I, Ferlay J, et al. Global incidence of oesophageal cancer by histological subtype in 2012[J]. Gut, 2015,64(3):381-387.
[3] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132.
[4] Abnet C C, Arnold M, Wei W Q. Epidemiology of esophageal squamous cell carcinoma[J]. Gastroenterology, 2018,154(2):360-373.
[5] Ohashi S, Miyamoto S, Kikuchi O, et al. Recent advances from basic and clinical studies of esophageal squamous cell carcinoma[J]. Gastroenterology, 2015,149(7):1700-1715.
[6] Shin E, Kashiwagi Y, Kuriu T, et al. Doublecortin-like kinase enhances dendritic remodelling and negatively regulates synapse maturation[J]. Nat Commun, 2013,4:1440.
[7] Nakanishi Y, Seno H, Fukuoka A, et al. Dclk1 distinguishes between tumor and normal stem cells in the intestine[J]. Nat Genet, 2013,45(1):98-103.
[8] Westphalen C B, Asfaha S, Hayakawa Y, et al. Long-lived intestinal tuft cells serve as colon cancER-initiating cells[J]. J Clin Invest, 2014,124(3):1283-1295.
[9] Park S Y, Kim J Y, Choi J H, et al. Inhibition of LEF1-Mediated DCLK1 by niclosamide attenuates colorectal cancer stemness[J]. Clin Cancer Res, 2019,25(4):1415-1429.
[10] Chandrakesan P, Yao J, Qu D, et al. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells[J]. Mol Cancer, 2017,16(1):30.
[11] Gao T, Wang M, Xu L, et al. DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer[J]. J Cancer Res Clin Oncol, 2016,142(10):2131-2140.
[12] Ikezono Y, Koga H, Akiba J, et al. Pancreatic neuroendocrine tumors and EMT behavior are driven by the CSC marker DCLK1[J]. Mol Cancer Res, 2017,15(6):744-752.
[13] Li J, Wang Y, Ge J, et al. Doublecortin-like kinase 1(DCLK1) regulates B cell-specific moloney murine leukemia virus insertion site 1(Bmi-1) and is associated with metastasis and prognosis in pancreatic cancer[J]. Cell Physiol Biochem, 2018,51(1):262-277.
[14] Whorton J, Sureban S M, May R, et al. DCLK1 is detectable in plasma of patients with barrett's esophagus and esophageal adenocarcinoma[J]. Dig Dis Sci, 2015,60(2):509-513.
[15] Weygant N, Qu D, Berry W L, et al. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1[J]. Mol Cancer, 2014,13:103.
[16] Harada Y, Kazama S, Morikawa T, et al. Prognostic impact of doublecortin-like kinase 1 expression in locally advanced rectal cancer treated with preoperative chemoradiotherapy[J]. APMIS, 2018,126(6):486-493.
[17] Nishio K, Kimura K, Amano R, et al. Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma[J]. World J Gastroenterol, 2017,23(31):5764-5772.
[18] Abudureheman A, Ainiwaer J, Hou Z, et al. High MLL2 expression predicts poor prognosis and promotes tumor progression by inducing EMT in esophageal squamous cell carcinoma[J]. J Cancer Res Clin Oncol, 2018,144(6):1025-1035.
[19] Chandrakesan P, Weygant N, May R, et al. DCLK1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition[J]. Oncotarget, 2014,5(19):9269-9280.
[20] Ge Y, Weygant N, Qu D, et al. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer[J]. Int J Cancer, 2018,143(5):1162-1175.
[21] Shalem O, Sanjana NE, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells[J]. Science, 2014,343(6166):84-87.
[22] Boettcher M and McManus M T. Choosing the right tool for the Job:RNAi, TALEN, or CRISPR[J]. Mol Cell, 2015,58(4):575-585.